Allogene Therapeutics, Inc.
ALLO
$2.22
$0.073.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -8.12% | -22.39% | |||
| Gross Profit | 8.12% | 22.39% | |||
| SG&A Expenses | 0.25% | -3.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.56% | -17.52% | |||
| Operating Income | 5.56% | 17.52% | |||
| Income Before Tax | 6.26% | 18.73% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.26% | 18.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.26% | 18.73% | |||
| EBIT | 5.56% | 17.52% | |||
| EBITDA | 5.88% | 18.56% | |||
| EPS Basic | 7.94% | 19.85% | |||
| Normalized Basic EPS | 7.90% | 15.95% | |||
| EPS Diluted | 7.94% | 19.85% | |||
| Normalized Diluted EPS | 7.90% | 15.95% | |||
| Average Basic Shares Outstanding | 1.80% | 1.42% | |||
| Average Diluted Shares Outstanding | 1.80% | 1.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||